A Study of HS-10506 in Chinese Patients With Insomnia Disorder
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HS-10506 in Chinese Adult Patients With Insomnia Disorder
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Huan Yu Yu Principal Investigator
- Puhelinnumero: 021-54602182
- Sähköposti: dr.yuhuan@163.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Yuping Wang Wang Principal Investigator
- Puhelinnumero: 13501186298
- Sähköposti: wangyuping01@sina.cn
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- participants must be 18 to 65 years of age (inclusive 18, not inclusive 65);
- participants are required to voluntarily sign the informed consent form;
- Body mass index (BMI): BMI (weight/height2 [kg/m2]) must be in the range of 18 to 35 kg/m2 (inclusive);
- Participants must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria for insomnia disorder;
- Participants must have Insomnia Severity Index (ISI) scores ≥ 15 at screening and run-in period;
- Subjective sleep assessment: Participants must have an sSOL≥30 minutes, sWASO≥30 minutes, and sTST < 6.5 hours for at least three nights every week within one month prior to screening; and sSOL ≥ 30 minutes, sWASO≥30 minutes, and sTST < 6.5 hours for at least 3 nights from sleep diary in the last 7 consecutive days before V2 visit and V3 visit respectively;
- PSG: Participants must demonstrate a 2-night mean LPS ≥ 30 minutes with neither night < 20 minutes, a 2-night mean WASO ≥ 30 minutes with neither nigh < 20 minutes, and a 2-night mean TST < 7 hours.
Exclusion Criteria:
- Has history of/current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
- Has a Apnea-Hypopnea Index (AHI) ≥ 10 times/hour or periodic leg movement with arousal index (PLMAI) ≥ 10 times/hour monitored by PSG at V2 visit;
- Has history of/current neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or clinically significant and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases within the past 3 months prior to screening; or other systemic diseases that are inappropriate for the study;
- Has a Hamilton Anxiety Scale (HAM-A) score ≥ 14 or Hamilton Depression Scale (HAM-D-17) score ≥ 18;
- Has used any medication that may affect the pharmacokinetics of HS-10506 or GLP-1R-related single/multi-target drugs within the past 2 weeks or 5 half-lives of the medication;
- Has used any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;
- Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;
- Has been working across 3 or more time zones or shift work within 2 weeks prior to screening;
- Has taken more than 3 naps per week for > 1 hour each time within the past 2 weeks prior to screening;
- Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;
- Has a history of drug dependency or abuse within the past 1 year or showed positive in urine drug test at screening;
- Has a history of alcohol abuse within the past 1 year or can't obey the rules of alcohol restriction;
- Has a history of smoking ≥ 10 cigars daily within the past 3 months or can't obey the rules of cigar restriction;
- Has a history of caffeine consumption ≥ 600 mg per day or can't obey the rules of caffeine restriction;
- Previously participated in any clinical trial of HS-10506;
- Has any circumstances or conditions, which, in the opinion of the investigator, may affect the participant's full participation in the study or compliance with the protocol.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: HS-10506
Participants will receive HS-10506 tablets, orally, once nightly for 84 consecutive nights
|
HS-10506 tablet
|
|
Placebo Comparator: Placebo
Participants will receive placebo matched in appearance to HS-10506 tablets, orally, once nightly for 84 consecutive nights
|
Placebo tablet matched to HS-10506
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline of mean latency to persistent sleep (LPS) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
Aikaikkuna: Baseline, Night 27 and Night 28,Night 83 and Night 84
|
LPS was defined as the time in minutes from lights off to the first epoch of 20 consecutive epochs of non-wakefulness as measured by polysomnography (PSG)
|
Baseline, Night 27 and Night 28,Night 83 and Night 84
|
|
Change from baseline of mean wakefulness after sleep onset (WASO) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
Aikaikkuna: Baseline, Night 27 and Night 28, Night 83 and Night 84
|
WASO was defined as minutes of wake from the onset of persistent sleep until lights on as measured by PSG
|
Baseline, Night 27 and Night 28, Night 83 and Night 84
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change from baseline of subjective sleep onset latency (sSOL) under the treatment of HS-10506
Aikaikkuna: Baseline, Week 4, Week 12
|
sSOL: estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary
|
Baseline, Week 4, Week 12
|
|
Change from baseline in subjective sleep efficiency (sSE) under the treatment of HS-10506
Aikaikkuna: Baseline, Week 4, Week 12
|
sSE: the ratio of subjective total sleep time(sTST) to subjective time in bed, sTST: the total sleep time reported by the participant in sleep diary.
|
Baseline, Week 4, Week 12
|
|
Change from baseline in total sleep time (TST) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
Aikaikkuna: Baseline, Night 27 and Night 28, Night 83 and Night 84
|
TST was defined as the total sleep time in minutes, the total sleep time is the total amount of stages 1, 2, 3 non rapid eye-movement (NREM) and rapid-eye-movement (REM) sleep time, as measured by PSG
|
Baseline, Night 27 and Night 28, Night 83 and Night 84
|
|
Change from baseline in sleep efficiency (SE) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
Aikaikkuna: Baseline, Night 27 and Night 28, Night 83 and Night 84
|
SE was defined as percentage (%) of time spent in bed asleep, calculated as total sleep time (TST) divided by interval from lights off until lights on as measured by PSG multiplied by 100
|
Baseline, Night 27 and Night 28, Night 83 and Night 84
|
|
Change from baseline in subjective wake after sleep onset (sWASO) under the treatment of HS-10506
Aikaikkuna: Week 4, Week 12
|
sWASO: estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary
|
Week 4, Week 12
|
|
Change from baseline in subjective total sleep time (sTST) under the treatment of HS-10506
Aikaikkuna: Baseline, Week 4, Week 12
|
sTST: the total sleep time reported by the participant in sleep diary
|
Baseline, Week 4, Week 12
|
|
Incidence and severity of adverse events (AE)
Aikaikkuna: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months
|
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months
|
|
Incidence and severity of serious adverse events (SAE)
Aikaikkuna: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months
|
An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participants and/or may require medical or surgical intervention to prevent one of the outcomes listed above
|
From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months
|
|
Withdrawal symptoms by Physician Withdrawal Checklist (PWC-20)
Aikaikkuna: The day after the last administration and at least 3 days after discontinuation of the medication
|
PWC-20 is a 20-item questionnaire and the score of each item ranges from 0-3 (0=not present, 1=mild, 2=moderate, 3=severe) with higher scores indicating greater severity of withdrawal symptoms
|
The day after the last administration and at least 3 days after discontinuation of the medication
|
|
Rebound insomnia by sleep diary during the follow-up period
Aikaikkuna: Baseline, Follow-up Period (3-6 days)
|
Rebound insomnia is defined as worsened sleep relative to baseline after study drug treatment was completed, rebound insomnia is assessed using the data collected in sleep diary, including estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary (subjective sleep onset latency, sSOL), estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary (subjective wake after sleep onset, sWASO) and the total sleep time reported by the participant in sleep diary ( subjective total sleep time, sTST)
|
Baseline, Follow-up Period (3-6 days)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- HS-10506-301
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .